Key highlights
- Nasdaq deficiency notice received on October 21, 2026, due to sub-$1.00 closing price
- Company granted an initial 180-day grace period to meet listing requirements
- Compliance requires a minimum closing bid of $1.00 for at least 10 consecutive days
- Management evaluating a potential reverse stock split to cure the deficiency
- Current cash resources projected to fund operations for at least two years
Compliance Deficiency Details
Akebia Therapeutics received a formal notification from the Nasdaq Listing Qualifications Department on October 21, 2026. The notice was triggered because the company's common stock failed to maintain a minimum bid price of $1.00 per share over a 30-day period, as required by Nasdaq Listing Rule 5550(a)(2). This deficiency does not result in an immediate delisting, and the common stock will continue to trade under the ticker AKBA. The company now enters an initial 180-day compliance period, which concludes on April 19, 2027, during which it must restore its share price to the required threshold.
Down 20.9% since our story on 23 Oct: $0.57 when we broke it → $0.45 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $0.68 |
|---|---|
| 20 Oct | $0.62 |
| 21 Oct | $0.58 |
| 22 Oct | $0.56 |
| 23 Oct | $0.57 |
| 26 Oct | $0.64 |
| 27 Oct | $0.66 |
| 28 Oct | $0.77 |
| 29 Oct | $0.74 |
| 30 Oct | $0.71 |
| 2 Nov | $0.71 |
| 3 Nov | $0.73 |
| 4 Nov | $0.69 |
| 5 Nov | $0.43 |
| 6 Nov | $0.40 |
| 9 Nov | $0.53 |
| 10 Nov | $0.54 |
| 11 Nov | $0.57 |
| 12 Nov | $0.50 |
| 13 Nov | $0.47 |
| 16 Nov | $0.45 |
Path to Regaining Compliance
- Stock must close at $1.00 or higher for 10 consecutive business days before April 19, 2027.
- A second 180-day extension may be available if the company meets other listing standards.
- Management is considering a reverse stock split as a potential remedy for the low share price.
- Failure to meet requirements by the deadline could trigger a formal delisting notice.
- Any delisting determination can be appealed to a Nasdaq Hearings Panel to maintain the listing.
Business and Clinical Pipeline
Based in Waltham, Massachusetts, Akebia Therapeutics focuses on renal disease treatments, led by its flagship product Vafseo. The company recently reported significant clinical progress, including the early halting of the Phase 3 VOICE trial in June 2026 due to superior safety and efficacy results. Akebia is also advancing ebribafusp into Phase 2 trials for rare kidney diseases. Despite these clinical milestones, the company faces commercial headwinds as its Auryxia product enters a period of expected revenue decline due to increasing generic competition in the pharmaceutical market.
Financial Performance and Market Position
The company reported total quarterly revenues of $49.1 million for the second quarter of 2026. While Akebia maintains a cash runway expected to last at least two years, market sentiment has been pressured, with the stock price falling approximately 55.01% over the last quarter. Technical indicators show a Relative Strength Index of 20.9, placing the stock in oversold territory. The recent resignation of the Chief Commercial Officer in October 2026 adds to the organizational shifts as the firm attempts to stabilize its market valuation and satisfy regulatory listing mandates.
| Date | Announcement | Amount |
|---|---|---|
| 14 Oct 2026 | Resignation of Senior Vice President and Chief Commercial Officer Nicholas Grund announced via Form 8-KSource: SEC filing | – |
| 06 Oct 2026 | Late-breaking presentation of VOICE trial results scheduled for ASN Kidney Week 2026Source: ir.akebia.com | – |
| 14 Sep 2026 | First patient dosed in Phase 2 basket trial of ebribafusp for rare complement-mediated kidney diseasesSource: ir.akebia.com | – |
| 05 Aug 2026 | Second quarter 2026 financial results reported with total quarterly revenues of $49.1 millionSource: globenewswire.com | $49.1 Million |
| 30 Jun 2026 | Phase 3 VOICE collaborative trial halted early after planned interim analysis showed superior safety outcomes for Vafseo versus ESAsSource: ir.akebia.com | – |
| 07 May 2026 | First quarter 2026 financial results reported with total net product revenues of $52.0 millionSource: ir.akebia.com | $52.0 Million |
| Share price | $0.57 |
|---|---|
| Market cap | $157M |
| Revenue (annual) | $236M |
| 1-month price change | -39.24% |
| Sector | HealthcareDrug Manufacturers - Specialty & Generic |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Akebia Therapeutics, Inc. announcing the receipt of a Nasdaq minimum bid price deficiency notice.
Track Akebia Therapeutics, Inc. live
Get the next Akebia Therapeutics, Inc. SEC filing seconds after it lands.